Skip to Main Content

Author Details

William H Bisson
Knight Cancer Institute, Oregon Health & Science University
2001
70
34
PMIDPaper TitleJournal TitlePublished Year
36997700OregonFluor enables quantitative intracellular paired agent imaging to assess drug target availability in live cells and tissues.Nat Chem2023
37117771Publisher Correction: OregonFluor enables quantitative intracellular paired agent imaging to assess drug target availability in live cells and tissues.Nat Chem2023
35785321Correction to "Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase".ACS Omega2022
35647450Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase.ACS Omega2022
32315394Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms.Blood2020
31668326A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib.J Thorac Oncol2019
29040756TCDD, FICZ, and Other High Affinity AhR Ligands Dose-Dependently Determine the Fate of CD4+ T Cell Differentiation.Toxicol Sci2018
30248327Evidence of selective activation of aryl hydrocarbon receptor nongenomic calcium signaling by pyrene.Biochem Pharmacol2018
30397356Gut microbiota and intestinal FXR mediate the clinical benefits of metformin.Nat Med2018
29581250LSD1 activates a lethal prostate cancer gene network independently of its demethylase function.Proc Natl Acad Sci U S A2018
29691238Structure-Activity Relationships of the Main Bioactive Constituents of <i>Euodia rutaecarpa</i> on Aryl Hydrocarbon Receptor Activation and Associated Bile Acid Homeostasis.Drug Metab Dispos2018
27517672Low-Dose Mixture Hypothesis of Carcinogenesis Workshop: Scientific Underpinnings and Research Recommendations.Environ Health Perspect2017
28275683Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions.Cell Mol Gastroenterol Hepatol2017
28186253Mechanistic Investigations Into the Developmental Toxicity of Nitrated and Heterocyclic PAHs.Toxicol Sci2017
29194351Identification of a Raloxifene Analog That Promotes AhR-Mediated Apoptosis in Cancer Cells.Biology (Basel)2017
27951515Polyphenolics from mango (Mangifera indica L.) suppress breast cancer ductal carcinoma in situ proliferation through activation of AMPK pathway and suppression of mTOR in athymic nude mice.J Nutr Biochem2017
27028006Comparison of anti-inflammatory mechanisms of mango (Mangifera Indica L.) and pomegranate (Punica Granatum L.) in a preclinical model of colitis.Mol Nutr Food Res2016
26303421Histone and Non-Histone Targets of Dietary Deacetylase Inhibitors.Curr Top Med Chem2016
27596062Conformational modulation of the farnesoid X receptor by prenylflavonoids: Insights from hydrogen deuterium exchange mass spectrometry (HDX-MS), fluorescence titration and molecular docking studies.Biochim Biophys Acta2016
27486223Divergent Ah Receptor Ligand Selectivity during Hominin Evolution.Mol Biol Evol2016
25747705Inhibition of farnesoid X receptor signaling shows beneficial effects in human obesity.J Hepatol2015
26670557Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction.Nat Commun2015
26106142Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead.Carcinogenesis2015
26106145Disruptive environmental chemicals and cellular mechanisms that confer resistance to cell death.Carcinogenesis2015
26106144Causes of genome instability: the effect of low dose chemical exposures in modern society.Carcinogenesis2015
26106141Environmental immune disruptors, inflammation and cancer risk.Carcinogenesis2015
26106143The potential for chemical mixtures from the environment to enable the cancer hallmark of sustained proliferative signalling.Carcinogenesis2015
26106135The impact of low-dose carcinogens and environmental disruptors on tissue invasion and metastasis.Carcinogenesis2015
26106137Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesis.Carcinogenesis2015
26106140Metabolic reprogramming and dysregulated metabolism: cause, consequence and/or enabler of environmental carcinogenesis?Carcinogenesis2015
26106138Disruptive chemicals, senescence and immortality.Carcinogenesis2015
26106139Mechanisms of environmental chemicals that enable the cancer hallmark of evasion of growth suppression.Carcinogenesis2015
26106136The effect of environmental chemicals on the tumor microenvironment.Carcinogenesis2015
26235394Adaptation of the human aryl hydrocarbon receptor to sense microbiota-derived indoles.Sci Rep2015
26141390Ligand-Specific Transcriptional Mechanisms Underlie Aryl Hydrocarbon Receptor-Mediated Developmental Toxicity of Oxygenated PAHs.Toxicol Sci2015
25867062Anti-androgen flutamide suppresses hepatocellular carcinoma cell proliferation via the aryl hydrocarbon receptor mediated induction of transforming growth factor-β1.Oncogene2015
26002081Chemical compounds from anthropogenic environment and immune evasion mechanisms: potential interactions.Carcinogenesis2015
24468632Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors.Bioorg Med Chem2014
25329374A Structural Switch between Agonist and Antagonist Bound Conformations for a Ligand-Optimized Model of the Human Aryl Hydrocarbon Receptor Ligand Binding Domain.Biology (Basel)2014
25321483HDAC8 and STAT3 repress BMF gene activity in colon cancer cells.Cell Death Dis2014
24865613Mono-substituted isopropylated triaryl phosphate, a major component of Firemaster 550, is an AHR agonist that exhibits AHR-independent cardiotoxicity in zebrafish.Aquat Toxicol2014
24580531Differences in conformational dynamics between Plasmodium falciparum and human Hsp90 orthologues enable the structure-based discovery of pathogen-selective inhibitors.J Med Chem2014
24481452The aryl hydrocarbon receptor mediates raloxifene-induced apoptosis in estrogen receptor-negative hepatoma and breast cancer cells.Cell Death Dis2014
23239810Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors.Mol Cancer Res2013
23770684HDAC turnover, CtIP acetylation and dysregulated DNA damage signaling in colon cancer cells treated with sulforaphane and related dietary isothiocyanates.Epigenetics2013
22242167AHR2 mutant reveals functional diversity of aryl hydrocarbon receptors in zebrafish.PLoS One2012
23116467Drug repurposing in chemical genomics: can we learn from the past to improve the future?Curr Top Med Chem2012
23116465Editorial: computational chemogenomics in drug design and discovery.Curr Top Med Chem2012
22634227Alternate glucocorticoid receptor ligand binding structures influence outcomes in an in vivo tissue regeneration model.Comp Biochem Physiol C Toxicol Pharmacol2012
21163906Estrogen-like activity of perfluoroalkyl acids in vivo and interaction with human and rainbow trout estrogen receptors in vitro.Toxicol Sci2011
  • 1 - 50 of 70

Recommended Authors

Centre Hospitalier Universitaire Sainte-Justine Research Centre
Career Start Year 2011
Number of shared co-authors 0
Ontario Institute for Cancer Research, University Avenue
Career Start Year 2007
Number of shared co-authors 0
St. Jude Children's Research Hospital
Career Start Year 2007
Number of shared co-authors 0
INSERM UMR-S1124, Universite Paris Cite
Career Start Year 2005
Number of shared co-authors 0
National Center for Advancing Translational Sciences, National Institutes of Health
Career Start Year 2003
Number of shared co-authors 1
Post Graduate Institute of Medical Education and Research
Career Start Year 2003
Number of shared co-authors 0
St. Jude Children's Research Hospital
Career Start Year 2003
Number of shared co-authors 0
National Center for Advancing Translational Sciences, National Institutes of Health
Career Start Year 2002
Number of shared co-authors 1
Inc. 16 Dekalb Pike
Career Start Year 2002
Number of shared co-authors 0
Center for Cancer Research, National Cancer Institute
Career Start Year 2001
Number of shared co-authors 0
National Institute of Environmental Health Sciences
Career Start Year 2000
Number of shared co-authors 0
Ontario Institute for Cancer Research, University Avenue
Career Start Year 1999
Number of shared co-authors 0
Institute for Data Science and Computing, University of Miami
Career Start Year 1998
Number of shared co-authors 1
Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences
Career Start Year 1998
Number of shared co-authors 0
St. Jude Children's Research Hospital
Career Start Year 1997
Number of shared co-authors 0
University of New Mexico School of Medicine
Career Start Year 1995
Number of shared co-authors 0
National Center for Advancing Translational Sciences, National Institutes of Health
Career Start Year 1994
Number of shared co-authors 0
Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Career Start Year 1994
Number of shared co-authors 1
The University of Danang-University of Science and Technology
Career Start Year 1993
Number of shared co-authors 0
National Center for Advancing Translational Science, 9800 Medical Center Drive
Career Start Year 1993
Number of shared co-authors 1
Expert Systems Inc.
Career Start Year 1993
Number of shared co-authors 1
Atux Iskay LLC
Career Start Year 1993
Number of shared co-authors 0
National Institutes of Health, National Center for Advancing Translational Sciences
Career Start Year 1992
Number of shared co-authors 1
National Institute of Allergy and Infectious Diseases, National Institutes of Health
Career Start Year 1990
Number of shared co-authors 0
St. George's University Medical School
Career Start Year 1990
Number of shared co-authors 0
Novartis
Career Start Year 1988
Number of shared co-authors 0
The Scripps Research Institute
Career Start Year 1987
Number of shared co-authors 0
Department of Pharmaceutical Sciences, University of Perugia
Career Start Year 1986
Number of shared co-authors 0
Broad Institute
Career Start Year 1985
Number of shared co-authors 1
Institute of Pharmaceutical Chemistry, Goethe University
Career Start Year 1983
Number of shared co-authors 0

Collaborators

Dasman Diabetes Institute
Co-authored papers 12
Co-authored papers 12
Cumming School of Medicine, University of Calgary
Co-authored papers 9
Co-authored papers 4
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California
Co-authored papers 4
Co-authored papers 4
Linus Pauling Institute, Oregon State University
Co-authored papers 3
Co-authored papers 2
Incyte Research Institute, Incyte Corporation
Co-authored papers 2
Pacific Northwest National Laboratory
Co-authored papers 2
Oncode Institute
Co-authored papers 2
Geisel School of Medicine at Dartmouth and US Department of Veterans Affairs
Co-authored papers 2
Co-authored papers 2
Oregon Health & Science University, University of California Berkeley
Co-authored papers 2
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 2
Oregon State University
Co-authored papers 2
UF Health Cancer Center
Co-authored papers 1
Oregon Health & Science University
Co-authored papers 1
Oregon Health Sciences University
Co-authored papers 1
Oregon State University
Co-authored papers 1
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 1
OHSU Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 1
Knight Cancer Institute.
Co-authored papers 1
Duke University Nicholas School of the Environment.
Co-authored papers 1
Oregon Health & Science University
Co-authored papers 1
Center for Health Research, Kaiser Permanente Northwest Research Center
Co-authored papers 1
Knight Cancer Institute and.
Co-authored papers 1
Huntsman Cancer Institute, University of Utah
Co-authored papers 1
Institute for Advanced Study, Technical University Munich
Co-authored papers 1
Rogel Cancer Center, University of Michigan ann arbor
Co-authored papers 1